Chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, is a heterogeneous lung condition characterized by chronic respiratory symptoms caused by persistent airflow limitation due to airway and alveolar abnormalities. Initial COPD management relies on bronchodilators with the addition of inhaled corticosteroids for those at high risk for exacerbations. However, up to half of patients on triple therapy still experience exacerbations, highlighting a need for new therapies. Biologic therapy targeting type 2 inflammation, which is common in COPD and associated with exacerbation risk, has recently been approved for clinical use as add-on maintenance treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. This educational program is designed to get pulmonology experts up to date on these rapid treatment advances for COPD as well as to bolster standard-of-care fundamentals.
CME/CE Accreditation Information
Asthma is a chronic lung disease characterized by persistent inflammation of respiratory airways that may lead to remodeling and further complications if not managed appropriately. This educational program aims to equip participants with the skills to accurately identify patients with severe asthma and initiate timely referrals to specialists for accurate diagnosis and optimization of treatment plans. Topics include the classification of asthma endotypes to guide treatment decisions with biologics and the incorporation of multidisciplinary care models in asthma and comorbidity management, all to improve treatment outcomes and patients’ quality of life.
CME/CE Accreditation Information
Considering the significant impact Prurigo Nodularis (PN) has on patients’ quality of life, it is critical for patients to receive a timely diagnosis and oftentimes can be difficult to treat. Furthermore, understanding the underlying pathogenesis is important to determine the optimal treatment approach. This curriculum presents the pathogenesis of PN, impact it has on patients’ quality of life, recommendations for its diagnostic workup, and novel evidence-based treatment approaches and strategies to individualize therapy for patients with PN.
CME/CE Accreditation Information
In this novel twist on a medical school staple of the peer-led study group, the Virtual Study Group provides a combination of collaborative and self-directed learning in a multi-interventional curriculum to delve more deeply into the multiple aspects of Multiple Myeloma diagnosis, workup, risk assessment, treatment, and patient care. Led by a local expert faculty, the Virtual Study Group includes cased-based presentations, discussions of clinical studies and expert guidelines as well as local considerations and cultural competencies. Learners will engage in assessments, self-study modules, and group activities, as well as live, online highly interactive meetings. This novel approach to learning complements the Multiple Myeloma webcast and provides deeper absorption of critical clinical information and its context to daily practice. How to claim credit Learners have the opportunity to earn up to a total of 2.5 CE for their participation in this small private online course curriculum. Credit will be awarded commensurate with leaner participation in the distinct components of the course curriculum. Learners who participate in all of the self-study curriculum components are eligible to earn 1.25 CE hours. Learners who also participate in the Live Group Discussions and the Group Task are eligible to earn additional CE; up to 1.25 CE hours commensurate with participation. These learners will be sent an email with instructions on how to claim this CE credit. Supporter Acknowledgement This activity is supported by an educational grant from Sanofi Genzyme, Karyopharm, and Janssen Biotech, Inc.
